Final results of a phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer.

被引：0
|
作者：
Swensen, Ron E.
Goff, Barbara Ann
Childs, Jennifer
Higgins, Doreen
Gooley, Theodore
Fintak, Patricia A.
Buening, Barbara
Disis, Mary L.
机构：
[1] Loma Linda Univ, Loma Linda, CA 92350 USA
[2] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA
[3] Univ Washington, Tumor Vaccine Grp, Seattle, WA 98195 USA
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[5] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5082
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer
    Qin, Yi
    Huang, Shangke
    Tang, Junli
    Fan, Yu
    Deng, Xiangyu
    Guan, Ping
    Zhang, Zhenhua
    Wen, Qinglian
    Li, Dan
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [32] Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer
    Colombo, Nicoletta
    Tomao, Federica
    Panici, Pierluigi Benedetti
    Nicoletto, Maria Ornella
    Tognon, Germana
    Bologna, Alessandra
    Lissoni, Andrea Alberto
    DeCensi, Andrea
    Lapresa, Mariateresa
    Mancari, Rosanna
    Palaia, Innocenza
    Tasca, Giulia
    Tettamanzi, Francesca
    Alvisi, Maria Francesca
    Rulli, Eliana
    Poli, Davide
    Carlucci, Luciano
    Torri, Valter
    Fossati, Roldano
    Biagioli, Elena
    GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 505 - 513
  • [33] Phase I/II study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Chelariu-Raicu, Anca
    Levenback, Charles F.
    Slomovitz, Brian M.
    Bodurka, Diane C.
    Gershenson, David Marc
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Relacorilant plus Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study
    Colombo, Nicoletta
    Van Gorp, Toon
    Matulonis, Ursula A.
    Oaknin, Ana
    Grisham, Rachel N.
    Fleming, Gini F.
    Olawaiye, Alexander B.
    Nguyen, Dorothy D.
    Greenstein, Andrew E.
    Custodio, Joseph M.
    Pashova, Hristina I.
    Tudor, Iulia C.
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30) : 4779 - +
  • [35] Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
    Walsh, Christine S.
    Kamrava, Mitchell
    Rogatko, Andre
    Kim, Sungjin
    Li, Andrew
    Cass, Ilana
    Karlan, Beth
    Rimel, Bobbie J.
    PLOS ONE, 2021, 16 (06):
  • [36] A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study
    Coleman, R. L.
    Brady, W.
    McMeekin, D. S.
    Rose, P. G.
    Soper, J. T.
    Lentz, S. S.
    Hoffman, J. S.
    Shahin, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel plus /- novel agents in platinum-resistant ovarian cancer: Vistusertib
    Banerjee, S.
    Lewsley, L-A.
    Clamp, A. R.
    Krell, J.
    Herbertson, R.
    Glasspool, R. M.
    Orbegoso, C.
    Green, C.
    Kristeleit, R. S.
    Gourley, C.
    Cambell, C.
    Banerji, U.
    Shepherd, C.
    Brugger, W.
    Chudleigh, L.
    Hanif, A.
    McNeish, I. A.
    Paul, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 403 - +
  • [38] Rosella (GOG-3073, ENGOT-OV72/MITO): a phase 3 study of relacorilant plus nab paclitaxel vs. nab-paclitaxel in platinum-resistant ovarian cancer
    Lorusso, Domenica
    Bagameri, Andrea
    Bishop, Erin
    Chudecka-Glaz, Anita
    Devaux, Alix
    Gladieff, Laurence
    Gordinier, Mary
    Kim, Jae-Weon
    Korach, Jacob
    Mccollum, Michael
    Mileshkin, Linda
    Monk, Bradley
    Nicum, Shibani
    Nogueira-Rodrigues, Angelica
    Oaknin, Ana
    O'Malley, David
    Orlando, Mauro
    Dreiling, Lyndah
    Tudor, Iulia Cristina
    Olawaiye, Alexander
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A255 - A255
  • [39] OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer
    McNeish, I. A.
    Moreno, V.
    Jayson, G.
    Roxburgh, P.
    Barretina Ginesta, M. P.
    Garcia-Donas, J.
    Anton Torres, A.
    Michael, A.
    Brown, R.
    Krige, D.
    Bendall, J.
    Di Genova, G.
    McElwaine-Johnn, H.
    ANNALS OF ONCOLOGY, 2019, 30 : 421 - 421
  • [40] NAB-PACLITAXEL IN THE TREATMENT OF ADVANCED PANCREATIC CANCER REFRACTORY TO GEMCITABINE - FINAL RESULTS OF A PHASE 2 TRIAL
    Lopes, G. de Lima
    Hosein, P.
    Gomez, C.
    Pastorini, V.
    Macintyre, J.
    Easey, M.
    Reis, I.
    Merchan, J.
    Bejarano, P.
    Rocha-Lima, C.
    EJC SUPPLEMENTS, 2011, 9 (01): : 1 - 1
12345